ONO-4538 Phase II Rollover Study (ONO-4538-98)
About the study
This study is intended to confirm the long-term safety of ONO-4538 in pan-tumor participants being treated with ONO-4538 monotherapy or in Combination with Other Therapies in clinical trials.
Who can take part
You may be eligible to participate in the study if you meet the following criteria:
INCLUSION CRITERIA
Inclusion Criteria:
- Participant who is being treated with ONO-4538 as monotherapy or in Combination with Other Therapies in clinical trials
- Participant who is eligible for ONO-4538 monotherapy or in combination with other therapies as per the clinical trials, and/or investigator-assessed clinical benefit
EXCLUSION CRITERIA
Exclusion Criteria:
- Participant judged to be incapable of providing consent for reasons such as concurrent dementia
- Participant judged by the investigator to be inappropriate as participants of this study
Study Locations
Enter your ZIP code/Postal code/PIN code to locate study sites near you:
How to Apply
Contact the study center to learn if this study is a good match for you.
Study’s details
Contition
Pan-tumor
Age (in years)
16+
Phase
Phase 2
Participants needed
59
Est. Completion Date
Dec 31, 2026
Treatment type
Interventional
Sponsor
Ono Pharmaceutical Co. Ltd
ClinicalTrials.gov identifier
NCT04566380
Study number
ONO-4538-98
Understanding Clinical Trials
Get answers to your questions about clinical trials.What is a clinical research?What does taking part in clinical trials involve?What should I ask the trial doctor?